Global Schizophrenia Therapeutics Market Size, Status and Forecast 2020-2026

  • receipt Report ID : 30184
  • calendar_today Published On: Apr, 2020
  • file_copy Pages: 92
  • list Pharmaceuticals and Healthcare

Schizophrenia therapeutics are used as a standard treatment regimen for schizophrenia. It helps in reversing the low levels of dopamine and serotonin, thereby improving the patient's condition.

The second-generation antipsychotic drugs segment accounted for the majority market shares because these drugs involve less side effects in comparison to their predecessors. The second-generation antipsychotic drugs are also called as atypical antipsychotic drugs. The increased efficacy and reduced side effects of these drugs improves the negative symptoms, decreases extrapyramidal side-effects (EPSE), and normalizes the level of prolactin. The improvement in negative and cognitive symptoms and the reduction in occurrences of EPSE is attributed to their antagonizing action on serotonin or 5-HT2A receptors. This in turn, will boost the segment’s growth throughout the estimated period.

In 2020, the global Schizophrenia Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2026, with a CAGR of xx% during 2020-2026.

This report focuses on the global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Schizophrenia Therapeutics development in United States, Europe and China.

The key players covered in this study

AstraZeneca

Eli Lilly

GlaxoSmithKline

Johnson & Johnson

Alkermes

AbbVie

Amgen

Bristol-Myers Squibb

Market segment by Type, the product can be split into

First-Generation Antipsychotic Drugs

Second-Generation Antipsychotic Drugs

Third-Generation Antipsychotic Drugs

Market segment by Application, split into

Hospitals

Clinics

Other

Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Schizophrenia Therapeutics status, future forecast, growth opportunity, key market and key players.

To present the Schizophrenia Therapeutics development in United States, Europe and China.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Schizophrenia Therapeutics are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered

1.4 Market Analysis by Type

1.4.1 Global Schizophrenia Therapeutics Market Size Growth Rate by Type (2015-2026)

1.4.2 First-Generation Antipsychotic Drugs

1.4.3 Second-Generation Antipsychotic Drugs

1.4.4 Third-Generation Antipsychotic Drugs

1.5 Market by Application

1.5.1 Global Schizophrenia Therapeutics Market Share by Application (2015-2026)

1.5.2 Hospitals

1.5.3 Clinics

1.5.4 Other

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Schizophrenia Therapeutics Market Size

2.2 Schizophrenia Therapeutics Growth Trends by Regions

2.2.1 Schizophrenia Therapeutics Market Size by Regions (2015-2026)

2.2.2 Schizophrenia Therapeutics Market Share by Regions (2015-2020)

2.3 Industry Trends

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Opportunities

3 Market Share by Key Players

3.1 Schizophrenia Therapeutics Market Size by Manufacturers

3.1.1 Global Schizophrenia Therapeutics Revenue by Manufacturers (2015-2020)

3.1.2 Global Schizophrenia Therapeutics Revenue Market Share by Manufacturers (2015-2020)

3.1.3 Global Schizophrenia Therapeutics Market Concentration Ratio (CR5 and HHI)

3.2 Schizophrenia Therapeutics Key Players Head office and Area Served

3.3 Key Players Schizophrenia Therapeutics Product/Solution/Service

3.4 Date of Enter into Schizophrenia Therapeutics Market

3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

4.1 Global Schizophrenia Therapeutics Market Size by Type (2015-2020)

4.2 Global Schizophrenia Therapeutics Market Size by Application (2015-2020)

5 United States

5.1 United States Schizophrenia Therapeutics Market Size (2015-2020)

5.2 Schizophrenia Therapeutics Key Players in United States

5.3 United States Schizophrenia Therapeutics Market Size by Type

5.4 United States Schizophrenia Therapeutics Market Size by Application

6 Europe

6.1 Europe Schizophrenia Therapeutics Market Size (2015-2020)

6.2 Schizophrenia Therapeutics Key Players in Europe

6.3 Europe Schizophrenia Therapeutics Market Size by Type

6.4 Europe Schizophrenia Therapeutics Market Size by Application

7 China

7.1 China Schizophrenia Therapeutics Market Size (2015-2020)

7.2 Schizophrenia Therapeutics Key Players in China

7.3 China Schizophrenia Therapeutics Market Size by Type

7.4 China Schizophrenia Therapeutics Market Size by Application

8 Japan

8.1 Japan Schizophrenia Therapeutics Market Size (2015-2020)

8.2 Schizophrenia Therapeutics Key Players in Japan

8.3 Japan Schizophrenia Therapeutics Market Size by Type

8.4 Japan Schizophrenia Therapeutics Market Size by Application

9 Southeast Asia

9.1 Southeast Asia Schizophrenia Therapeutics Market Size (2015-2020)

9.2 Schizophrenia Therapeutics Key Players in Southeast Asia

9.3 Southeast Asia Schizophrenia Therapeutics Market Size by Type

9.4 Southeast Asia Schizophrenia Therapeutics Market Size by Application

10 India

10.1 India Schizophrenia Therapeutics Market Size (2015-2020)

10.2 Schizophrenia Therapeutics Key Players in India

10.3 India Schizophrenia Therapeutics Market Size by Type

10.4 India Schizophrenia Therapeutics Market Size by Application

11 Central & South America

11.1 Central & South America Schizophrenia Therapeutics Market Size (2015-2020)

11.2 Schizophrenia Therapeutics Key Players in Central & South America

11.3 Central & South America Schizophrenia Therapeutics Market Size by Type

11.4 Central & South America Schizophrenia Therapeutics Market Size by Application

12 International Players Profiles

12.1 AstraZeneca

12.1.1 AstraZeneca Company Details

12.1.2 Company Description and Business Overview

12.1.3 Schizophrenia Therapeutics Introduction

12.1.4 AstraZeneca Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.1.5 AstraZeneca Recent Development

12.2 Eli Lilly

12.2.1 Eli Lilly Company Details

12.2.2 Company Description and Business Overview

12.2.3 Schizophrenia Therapeutics Introduction

12.2.4 Eli Lilly Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.2.5 Eli Lilly Recent Development

12.3 GlaxoSmithKline

12.3.1 GlaxoSmithKline Company Details

12.3.2 Company Description and Business Overview

12.3.3 Schizophrenia Therapeutics Introduction

12.3.4 GlaxoSmithKline Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.3.5 GlaxoSmithKline Recent Development

12.4 Johnson & Johnson

12.4.1 Johnson & Johnson Company Details

12.4.2 Company Description and Business Overview

12.4.3 Schizophrenia Therapeutics Introduction

12.4.4 Johnson & Johnson Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.4.5 Johnson & Johnson Recent Development

12.5 Alkermes

12.5.1 Alkermes Company Details

12.5.2 Company Description and Business Overview

12.5.3 Schizophrenia Therapeutics Introduction

12.5.4 Alkermes Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.5.5 Alkermes Recent Development

12.6 AbbVie

12.6.1 AbbVie Company Details

12.6.2 Company Description and Business Overview

12.6.3 Schizophrenia Therapeutics Introduction

12.6.4 AbbVie Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.6.5 AbbVie Recent Development

12.7 Amgen

12.7.1 Amgen Company Details

12.7.2 Company Description and Business Overview

12.7.3 Schizophrenia Therapeutics Introduction

12.7.4 Amgen Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.7.5 Amgen Recent Development

12.8 Bristol-Myers Squibb

12.8.1 Bristol-Myers Squibb Company Details

12.8.2 Company Description and Business Overview

12.8.3 Schizophrenia Therapeutics Introduction

12.8.4 Bristol-Myers Squibb Revenue in Schizophrenia Therapeutics Business (2015-2020)

12.8.5 Bristol-Myers Squibb Recent Development

13 Market Forecast 2020-2026

13.1 Market Size Forecast by Regions

13.2 United States

13.3 Europe

13.4 China

13.5 Japan

13.6 Southeast Asia

13.7 India

13.8 Central & South America

13.9 Market Size Forecast by Product (2020-2026)

13.10 Market Size Forecast by Application (2020-2026)

14 Analyst's Viewpoints/Conclusions

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Disclaimer

15.3 Author Details

List of Tables and Figures

Table Schizophrenia Therapeutics Key Market Segments

Table Key Players Schizophrenia Therapeutics Covered

Table Global Schizophrenia Therapeutics Market Size Gr

Please fill the form below, to recieve the report sample


+1